| Combination of | |
|---|---|
| Quinupristin | Antibiotic |
| Dalfopristin | Antibiotic |
| Clinical data | |
| Pregnancy cat. | B (U.S.) |
| Legal status | ℞-only (U.S.) |
| Routes | IV |
| Identifiers | |
| CAS number | 126602-89-9 |
| ATC code | J01FG02 |
| PubChem | CID 23724510 |
| ChemSpider | 21106373 |
| ChEMBL | CHEMBL1200649 |
| (what is this?) (verify) |
|
| Systematic (IUPAC) name | |
|---|---|
| N-{(6R,9S,10R,13S,15aS,18R,22S,24aS)-18-
{[(3S)-1-azabicyclo[2.2.2]oct-3-ylthio]methyl-22-[4-(dimethylamino)benzyl]- 6-ethyl-10,23-dimethyl-5,8,12,15,17,21,24-heptaoxo-13-phenyldocosahydro-12H- pyrido[2,1-f]pyrrolo-[2,1-l][1,4,7,10,13,16] oxapentaazacyclononadecin-9-yl}-3- hydroxypyridine-2-carboxamide |
|
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Pharmacokinetic data | |
| Half-life | 3.1 hours |
| Identifiers | |
| CAS number | 120138-50-3 |
| ATC code | ? |
| PubChem | CID 5388937 |
| Chemical data | |
| Formula | C53H67N9O10S |
| Mol. mass | 1022.24 g/mol |
Quinupristin/dalfopristin (trade name Synercid) is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.
Quinupristin and dalfopristin are both streptogramin antibiotics, derived from pristinamycin. Quinupristin is derived from pristinamycin IA; dalfopristin from pristinamycin IIA. They are combined in a weight-to-weight ratio of 30% quinupristin to 70% dalfopristin.
Contents |
Intravenous, usually 7.5 mg/kg every 8–12 hours
Quinupristin and dalfopristin are protein synthesis inhibitors in a synergestic manner. While each of the two is only a bacteriostatic agent, the combination shows bactericidal activity.
Clearance by the liver, half-life 1–3 hours (with persistence of effects for 9–10 hours).
Inhibits P450 and enhances the effects of terfenadine, astemizole, indinavir, midazolam, Ca channel blockers, warfarin, cisapride and cyclosporine.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||